US Rare Disease Bio Executive Sells $23 Million in Company Stock in Three Days... Realizes Option Gains

Martin Rothblatt, chairman of the board and CEO of United Therapeutics Corporation (NASDAQ: UTHR), exercised approximately 9,500 stock options on each of three occasions—May 29 and June 1 and 2—at about $146 per share, then sold the shares the same day on the open market at prices between $540 and $560 per share. Each sale generated roughly $5 million in proceeds, bringing the three-day total to about $15 million (approximately KRW 23 billion). As a result, his direct holdings fell slightly from around 50,000 shares to roughly 40,513 shares; however, including indirect holdings via his spouse and a family trust, he still owns over 640,000 shares. The transactions were conducted under a 10b5-1 trading plan established in November 2025, which the company notes may continue to structure option exercises and share sales until all of the roughly 1.73 million options—maturing in December 2026 or March 2027—are fully exercised.

Meanwhile, on June 29 United Therapeutics secured pre-market approval from the U.S. Food and Drug Administration for LungFX, its ex vivo lung perfusion platform for lung transplantation, strengthening its competitive edge in the organ-transplant and manufacturing business. The approval has drawn positive reactions from analysts. In May, alongside its Q1 2026 financial results, the company also approved a share repurchase program of up to $2 billion (about KRW 3 trillion), executing a substantial portion through an accelerated buyback to reinforce its shareholder-return strategy.

United Therapeutics is a U.S. biotech firm specializing in treatments for rare and severe cardiopulmonary diseases—such as pulmonary arterial hypertension—and in technologies to expand the supply of transplantable organs. It was founded in 1996 by Martin Rothblatt to develop a therapy for the pulmonary arterial hypertension that threatened his daughter’s life. Rothblatt, also known for founding satellite radio company SiriusXM, continues to lead United Therapeutics as its founder, board chair, and CEO.